The impact of influenza infection is felt globally each year when the disease develops in approximately 20 percent of the world's population. In the United States, influenza infections occur in ...

This winter, the circulating strain of seasonal influenza A virus (H1N1) is resistant to the neuraminidase inhibitor oseltamivir. Moreover, rather than emerging under selective pressure of drug ...

The study (“Broadly protective human antibodies that target the active site of influenza virus neuraminidase”) in Science, which Scripps Research conducted jointly with Washington University ...

NA activity was determined in 96-well white U-bottom microplates (Greiner bio-one GmbH, Frickenhausen, Germany) using the CL-based NA-Star assay (NA-Star Influenza Neuraminidase Inhibitor ...

The analysis of neuraminidase genetic sequences identified A46D, L204M, S319F, and S430G mutations that act synergistically to improve H5N1 viral fitness and adaptability in humans.

InDevR's game-changing VaxArray® vaccine potency testing platform now includes a reagent kit for rapid assessment of neuraminidase in influenza vaccines BOULDER COLORADO (6/12/18) -- InDevR Inc ...

We have demonstrated the safety and immunogenicity of individual monovalent ganglioside conjugate vaccines when administered with OPT821, a synthetic saponin adjuvant that augments the T-cell response ...

3 – 6 In this report, we summarize information about the safety of neuraminidase inhibitors for treatment of novel H1N1 influenza in pregnant and breastfeeding women. Although the information about ...

Aims In this study, we analyze the challenges involved in detecting novel neuraminidase inhibitors (NAIs) and offer strategies to overcome them with complementary bioassays. Materials & Methods We ...